|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 584 active entries
Ground Floor 10 St Andrew's Place
East Melbourne, 3002
Phone: +61 (0)3 9656 5804
Fax: +61 (0)3 9656 1650
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Cell Therapies Pty Ltd is a contract service provider supporting cell therapy clinical trials and commercial manufacture of human cells and tissue. A fully-integrated range of services covers all aspects of cell therapy manufacture, including production in compliance with Good Manufacturing Practices (cGMP), under TGA, EMA and FDA regulatory controls.
• Protocol design, validation and approvals
• SOP preparation
• Recruitment of investigators and patients
• Cell collection and logistics
• Process and analytical development, validation
• GMP manufacturing and QC testing (licensed facility)
• Cell therapy product administration
• Clinical interpretation and reporting
• Audit compliance
Based in the Peter MacCallum Cancer Centre and the Centre for Blood Cell Therapies, Cell Therapies can provide a one-stop shop for cell therapy trials or commercial manufacture. Our capacity to work with a wide range of cell types and clinical conditions has proven to be a powerful attraction for our clients. We can recruit patients from within our cancer related facility and/or in collaboration with other clinical sites., We deliver reliable trial results under demanding protocol and reporting regimens.
Other resources at the Peter MacCallum Cancer Centre can be incorporated into clinical studies as well. A state of the art Diagnostic Imaging suite, for example, offers clinical and research PET, MRI, CT, SPECT, combined PET-CT, and Ultrasound imaging capabilities. Our state of the art work with custom cell labelling, permitting in vivo tracking of administered cells can be particularly useful in answering biodistribution questions from regulatory authorities.
Last update of this entry: October 26, 2011